Macular Degeneration Foundation
EyeSight.org
Category: Basic Research
Breakthrough Research
The Macular Degeneration Foundation is pleased to announce that a team of researchers, funded by the MD Foundation, has made an important breakthrough. It is fully described in the following linked technical article entitled: “A Systems Biology Approach Uncovers Novel…
Read MoreProzac for Dry AMD?
NIH – National Library of Medicine An antidepressant best known as Prozac could offer the first treatment for macular degeneration according to new research from the University of Virginia School of Medicine. UVA’s Bradley D. Gelfand, PhD, and collaborators have…
Read MoreMicrocurrent Stimulation
Microcurrent Stimulation is the application of a small electrical current to tissues using electrodes placed on the skin. It has been used for years with FDA approval for the repair of injured soft tissues and for treating muscular-skeletal pain. Several…
Read More“The Complement System” – Simplified
We all know that our bodies have an immune system that protects us from infections. A special part of this protection is called the complement system, or just complement. It was first identified in the late 1800’s as something in…
Read MoreResearchers Study Worms
Using roundworms, the University of Maryland School of Medicine researchers believe they have identified a new and distinct cause of macular degeneration. The discovery offers the potential to identify new ways to treat the disease. “In order to find a…
Read MorePegcetacoplan Study Results
Press ReleaseWALTHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an…
Read More5 New Treatments on the Horizon
Newest Sustained-Release Anti-VEGF Drug in Trials EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for…
Read MoreCommon Misconceptions Regarding Macular Degeneration
by Dan RobertsMD Foundation Resource Director888-866-6148 Age-related macular degeneration (AMD) is a progressive disease of the retina wherein the light-sensing cells in the central area of vision (the macula) stop working and eventually die. The disease is thought to be…
Read MorePromising Update on APL-2 for Dry AMD
Statistically Significant Slowing of Disease Progression Seen at 12 Months APL-2 is a synthetic peptide which shuts down the complement activation system responsible for local inflammation, tissue damage (as in dry AMD) and the resulting blood vessel growth (angiogenesis in…
Read MoreNew Biomarker for AMD
by Adam Pope 1/23/19 Researchers from the University of Alabama at Birmingham Department of Ophthalmology and Visual Sciences, along with collaborators from the University of Iowa, have discovered a genetic biomarker that is associated with age-related macular degeneration and delayed rod-mediated…
Read MoreGenentech’s Faricimab for Wet AMD May Extend Time Between Injections
Genentech has announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). According to Sandra Horning, M.D., chief medical officer and head of Global…
Read MoreWatch Exclusive Research Video’s Produced by the MD Foundation
Macular Degeneration Foundation 